SPOTLIGHT: Heparin prices double since recalls

Since Baxter recalled virtually all its heparin products on reports of severe reactions and deaths, the price for the blood thinner has doubled. The sole U.S. supplier, APP Pharmaceuticals, says costs for crude Chinese heparin have risen fivefold since last year and recent price increases don't cover all its higher expenses. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.